This metabolic reprogramming enables anchorage-independent cancer cell survival, whereas RNF126 depletion or PDK1 overexpression suppresses both anchorage-independent growth and tumorigenicity, highlighting the ERK-RNF126-PDK axis as a potential therapeutic target for disrupting metastatic dissemination in breast cancer [9]. Here, RNF126 is linked to breast carcinoma.